MedTrace Logo

First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors

NCT07362888 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-04-15

No results posted yet for this study

Summary

The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.

Conditions

  • Solid Tumors (Phase 1)

Interventions

DRUG

ADCE-B05

Biological: Antibody-drug conjugate (ADC)

Sponsors & Collaborators

  • Adcendo ApS

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-17
Primary Completion
2026-12-31
Completion
2029-03-14
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07362888 on ClinicalTrials.gov